News & Updates

Prognosis for patients with HBV-related HCC better after tenofovir vs entecavir treatment

Patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) appear to fare better with tenofovir than with entecavir, with a recent study showing that prognosis is better for those who have been treated with tenofovir.

Garsorasib shows therapeutic potential in KRASG12C-mutated NSCLC

The investigational garsorasib, a potent KRASG12C inhibitor, appears to induce high response rate while having a manageable safety profile in patients with previously treated KRASG12C-mutated non–small cell lung cancer (NSCLC), according to the results of a phase II study.

Vitamin C may improve survival in low-risk myeloid malignancy

Vitamin C deficiency is not uncommon among patients with haematological cancer, but vitamin C supplementation can help address this condition and even provide a survival benefit, suggests a study presented at EHA 2024.

Aspirin for CRC prevention works better in presence of less healthy lifestyles

People with less healthy lifestyles appear to obtain greater protection against colorectal cancer (CRC) with aspirin use, according to a study.

Targeting PV source with ropeginterferon alfa-2b revolutionizes treatment

Polycythemia vera (PV) is a chronic myeloproliferative disorder characterized by overproduction of red blood cells, which poses a significant risk of thrombohaemorrhagic complications and impaired survival. Traditionally, treatment approaches have focused on managing the symptoms and reducing haematocrit levels, but these do not address the underlying cause of the disease.

Ropeginterferon alfa-2b (BESREMi, PharmaEssentia), an innovative monopegylated long-acting interferon, offers a novel approach by directly targeting and depleting JAK2-mutated hematopoietic stem cells (HSCs) in the bone marrow, which is the source of the disease. This article focuses on the role of ropeginterferon alfa-2b in transforming the treatment landscape for PV, its mechanisms, clinical benefits, and potential to significantly improve patient outcomes.

Female AYA cancer survivors: Are they at risk for adverse obstetric outcomes?

Female adolescent and young adult (AYA) survivors of certain types of cancer appear to be at risk of birth rate deficits and obstetric complications, suggests a retrospective study from the UK.